Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline ... The rate of HIV infection and the number of deaths ... a positive rate across the globe. It has been estimated ... to 1.5 in 2013, with the rates for children being ... in the infection rates has been the improved access to ...
(Date:8/18/2014)... DALLAS , August 18, 2014 ... "Membrane Bioreactor Systems Market, By Application (Municipal Wastewater ... Fiber, Flat Sheet and Multi Tubular), By Configuration ... to 2019", published by MarketsandMarkets, The market for ... million by 2019, growing at a CAGR of ...
(Date:8/18/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... on Form 10 with the U.S. Securities and ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form ...
(Date:8/18/2014)... , 18. August 2014 Vier ... eine internationale klinische Studie auf, in der ... Linse soll das Sehvermögen bei allen Entfernungen ... Operation möglicherweise keine Lese- oder Gleitsichtbrille mehr ... Namen FluidVision Accommodating Intraocular Lens ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... Holdings, Inc. (NYSE: ZMH ; SWX: ZMH) announced today ... broadcast live over the Internet on Thursday, July 23, 2009, at ... results will be made available at 7:00 a.m. the morning of ... be accessed via Zimmer,s Investor Relations website at ...
... Pa. and NEWTON, Mass., June 30 Microfluidics, ... (OTC Bulletin Board: MFLU), and Particle Sciences Inc. ... biopharmaceutical companies leverage the most advanced and reliable ... and commercialize Active Pharmaceutical Ingredients (APIs). , ...
... June 30 Hospira, Inc. (NYSE: HSP ... today announced agreements with MedAssets on intravenous (I.V.) solutions ... agreement for infusion devices. The five-year MedAssets agreements are ... and equipment, and July 1, 2009, for infusion devices. ...
Cached Biology Technology:Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 2Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 3Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2
(Date:8/19/2014)... MA -- MIT chemical engineers have devised a new ... are released slowly over a few weeks. When applied ... the body to rapidly form new bone that looks ... type of coated scaffold could offer a dramatic improvement ... involves transplanting bone from another part of the patient,s ...
(Date:8/19/2014)... today,s crocodiles colonised the seas during warm phases and ... Anglo-French study which establishes a link between marine crocodilian ... period of more than 140 million years. , ... Universit de Lyon, France and formerly from the University ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals that ...
(Date:8/19/2014)... A team of UTSA researchers has been awarded a ... Technology and Training (NCPTT), an office of the National ... The grant will fund a one-year study of the ... of historic homes in hot, humid climates. , Radiant ... or attics that reflect heat back, thereby reducing the ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3Evolution of marine crocodilians constrained by ocean temperatures 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Angeles New evidence from the University of Southern California ... that help compile small bits of information in order to ... professor of psychology in the area of brain and cognitive ... Public Library of Science journal, PLoS ONE. It ...
... MA--Boston University School of Medicine (BUSM) will present The Sixth ... 14, 2007 at noon. The annual lecture is in honor ... in BUSMs Pulmonary Center. Kim Hanson, along with her ... the second plane that struck the World Trade Center on ...
... University of Oregon has received a $1.6 million grant ... effects of exposure to precisely engineered nanoparticles that are ... three-year grant from the Keck Foundations medical research program ... Andy Berglund, all UO professors of chemistry; UO biology ...
Cached Biology News:Shape encoding may start in the retina 2Lecture to honor victim of Sept. 11 tragedy 2Keck Foundation funds study of biological interactions with nanomaterials 2
...
... measures NOS activity by monitoring the conversion ... is simple, sensitive, and specific for NOS ... crude and purified enzyme preparations. The kit ... total reactions. Radiolabeled arginine and NADPH are ...
Human TSLP MAb (Clone 258136)...
Human Complement Component C5a MAb (Clone 295003)...
Biology Products: